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Gestational vitamin A (retinol) deficiency poses a risk
for ocular birth defects and blindness. We identified
missensemutations inRBP4, encoding serum retinol
binding protein, in three families with eye malforma-
tions of differing severity, including bilateral anoph-
thalmia. The mutant phenotypes exhibit dominant
inheritance, but incomplete penetrance. Maternal
transmission significantly increases the probability
of phenotypic expression. RBP normally delivers
retinol from hepatic stores to peripheral tissues,
including the placenta and fetal eye. The diseasemu-
tations greatly reduce retinol binding to RBP, yet
paradoxically increase the affinity of RBP for its cell
surface receptor, STRA6. By occupying STRA6 non-
productively, the dominant-negative proteins disrupt
vitamin A delivery from wild-type proteins within the
fetus, but also, in the case of maternal transmission,
at the placenta. These findings establish a previously
uncharacterized mode of maternal inheritance,
distinct from imprinting and oocyte-derived mRNA,
and define a group of hereditary disorders plausibly
modulated by dietary vitamin A.
INTRODUCTION
Congenital eye malformations—including microphthalmia,
anophthalmia, and coloboma (MAC) disease—affect two in
10,000 births and are an important cause of childhood blindness
(Morrison et al., 2002). The severity depends on timing and the
extent that growth and morphogenesis of the developing eye
is disrupted (Graw, 2010). Anophthalmia, or total absence of
eyes, is the most extreme form. Microphthalmia (small eyes)
and coloboma (ventronasal notch-like defects in the iris and/or
retina, arising from incomplete closure of the choroid fissure,
see Onwochei et al., 2000) are less severe. These can occur as634 Cell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc.uni- or bilateral abnormalities, and may coexist in an individual
or pedigree. Most cases are isolated, but one-third are associ-
ated with systemic birth defects. Few genetic causes have
been identified (Williamson and FitzPatrick, 2014). Loss-of-func-
tion SOX2 mutations account for 10% of bilateral anophthalmia
(Fantes et al., 2003), whereas mutations in RX, CHX10, BCOR,
HCCS, and PAX6 transcription factors explain other monogenic
cases. Signaling pathways mediated by BMP4, GDF6, and SHH
may also be genetically disrupted. Finally, disease risk is
affected by environmental factors, such as maternal nutrition
(Hornby et al., 2003).
Vitamin A is an essential, fat-soluble nutrient for embryonic
development, tissue homeostasis, and physiology. Its most
widely recognized function is to supply the visual cycle with
11-cis-retinal (vitamin A aldehyde) for generation of the light-sen-
sitive visual pigment rhodopsin (Lamb and Pugh, 2004). Conse-
quently, vitamin A deficiency (VAD) first manifests as night
blindness (nyctalopia), a reversible loss of visual adaptation to
dark environments (Dowling and Wald, 1958). Vitamin A is also
required for epithelial, reproductive, and immune health. At the
molecular level, vitamin A is a substrate for synthesis of retinoic
acid (RA), a potent signaling molecule needed for vertebrate
organogenesis, including eye development (Duester, 2009; Nie-
derreither and Dolle´, 2008). Nutritional studies have long associ-
ated maternal vitamin A deficiency with eye malformations, as
well as urogenital, diaphragmatic, cardiovascular, and pulmo-
nary defects (Hale, 1933; See and Clagett-Dame, 2009; Wilson
et al., 1953). Recently, genetic links were established between
retinoid signaling defects and MAC disease. Loss-of-function
mutations in STRA6, encoding themembrane receptor for serum
retinol binding protein (RBP), cause autosomal recessive anoph-
thalmia or Matthew-Wood syndrome (OMIM 601186), character-
ized by structural eye defects, diaphragmatic hernias, cardiac
malformations, and pulmonary hypoplasia (Golzio et al., 2007;
Pasutto et al., 2007; Casey et al., 2011; Chassaing et al.,
2009). Likewise, mutations in ALDH1A3, encoding retinaldehyde
dehydrogenase, account for a subset of recessive MAC cases
(T.G., C.M.C., A.S., T.B., and N.M. Ghiasvand, unpublished
data; Fares-Taie et al., 2013; Yahyavi et al., 2013).
Figure 1. Familial MAC Disease
(A) Family 1 pedigree with two probands (arrows).
There are 11 family members with microphthalmia
or coloboma (gray symbols) or clinical anoph-
thalmia (black symbols) and 9 obligate carriers
(dotted symbols).
(B) Anterior eye and fundus photographs of family
members with iris or chorioretinal colobomas
(VI-2, VII-2, and VII-3), microphthalmia (III-12 and
VII-2), or bilateral clinical anophthalmia (VII-5) and
orbital MRI views of VII-5. The T2w coronal MRI
shows extraocular muscles (red arrowheads), but
absent eye globes. The T2wFS axial image shows
bilateral hyperintense orbital cysts (yellow arrow-
heads); optic nerve head, onh; chorioretinal colo-
boma, crc; left, L; and right, R. See also Table S1.
(C) Genetic mapping of MAC disease. (Top)
Multipoint LOD plot of autosomes, based on
affected individuals and obligate carriers. (Bottom)
Expanded linkage analysis favors chromosome 10
localization. See also Figures S1 and S2.Here, we show mutations in the serum RBP gene underlie an
autosomal dominant form ofMAC that is transmitted with incom-
plete penetrance and a unique maternal parent-of-origin effect
(Sturtevant, 1923). We further show that the unliganded mutant
RBPs bind STRA6 with much greater affinity than wild-type,
and consequently are likely to disrupt delivery of vitamin A to
target cells, consistent with a dominant-negative effect. These
results shed light on the maternal-fetal nutritional interface, ge-
netic susceptibility to vitamin A deficiency, and the etiology of
eye malformations.
RESULTS
Autosomal Dominant MAC Disease with Reduced
Penetrance and a Maternal Effect
A seven-generation pedigree (Family 1) was identified through
two probands with anophthalmia (Figure 1A). The pene-
trance of eye disease is incomplete (P = 0.4), based on 54
informative meioses (Figure S1A). Carriers have phenotypesCell 161, 634–6ranging from normal to microphthalmia
to complete absence of the eyes
(Figure 1B; Table S1). Several individuals
have iris and/or chorioretinal colobomas.
Transmission is skewed. Nearly all
affected individuals (10 of 11) inherited
the trait from their mother, such
that maternal penetrance is signifi-
cantly greater than paternal penetrance
(Pmat = 0.7, Ppat = 0.1; Figure S1B). In
the only instance of paternal transmis-
sion, one of two monozygous twins
(VI-2) was affected.
A New MAC Locus on Chromosome
10q23
We first excluded 23 loci associated
with MAC in humans or vertebratemodels (Table S2) by comparing haplotypes of the two pro-
bands. We then examined available family members and per-
formed genome-wide multipoint linkage analysis (Figures S1C
and S1D). We applied a simple autosomal dominant (AD)
model, scoring only affecteds and obligate carriers. This anal-
ysis suggested three candidate regions: 1q41, 10q23, and
19p13, with peak LOD scores >2 (Figure 1C). To rank these re-
gions, we included at-risk unaffected family members and
applied AD models with uniform (Pglobal = 0.4) or sex-specific
(Pmat = 0.7, Ppat = 0.1) penetrance. This indicated a chromo-
some 10q23 localization with peak LOD score of 3.01 (Fig-
ure 1C). The 8.2 megabases (Mb) nonrecombinant interval
contains 81 genes (Figure S2). Given the importance of vitamin
A in eye development (Warkany and Schraffenberger, 1946)
and eye malformations associated with STRA6 and ALDH1A3
mutations (T.G., C.M.C., A.S., T.B., and N.M. Ghiasvand, un-
published data); we tested genes in the critical region with
roles in vitamin A transport (RBP4) and RA metabolism
(CYP26A1 and C1).46, April 23, 2015 ª2015 Elsevier Inc. 635
Figure 2. RBP4Mutations in Three Indepen-
dent Families with Congenital Eye Malfor-
mations
(A) Map of 9.4 kilobases RBP4 gene, with signal
sequence (gray), mature protein (black) coding
regions, and MAC mutations (red box).
(B) Sequence chromatograms showing heterozy-
gous missense mutations, with maternal trans-
mission in each pedigree.
(C) Primary structure of translated RBPwith ala-to-
thr substitutions (red) in the mature polypeptide
(yellow bar) and two alleles associated with
recessive nyctalopia (gray). Note that A73T and
A75T in theprimary translationproduct correspond
to A55T and A57T following cleavage of the signal
sequence (gray bar, SS); cyan coils, a-helix; blue
arrows A–H; and b strands forming the b-barrel.
(D) Ribbon diagrams showing positions of domi-
nant (red) and recessive (gray) substitutions. There
are eight anti-parallel strands (dark blue) that
form the ligand pocket. There are three loops
(green) at the calyx opening contact TTR. The
N terminus is relatively unconstrained. See also
Figure S3D.
(E) Alignment showing conservation of alanines 55
and 57 among vertebrates.Dominant RBP4Mutations in Three Unrelated MAC
Families
RBP4 encodes serum RBP (Kanai et al., 1968) and contains six
exons (Figure 2A). Exon screening revealed a missense mutation
(c.223G>A, p.A75T) that cosegregated with the disease trait
(Figure 2B) and was not found in >11,330 control chromosomes.
We then screened a cohort of 75 unrelated MAC samples and
discovered mutations in two cases, a male with bilateral anoph-
thalmia and neurodevelopmental delay (Family 2), and a female
with left microphthalmia and coloboma (Family 3). They share a
single missense allele (c.217G>A, p.A73T) on distinct haplo-
types, indicating recurrence of themutation, withmaternal trans-
mission in both families (Figure S3).
p.A73T and p.A75T Alter the Retinol-Binding Surface
RBP mobilizes all-trans retinol from liver stores to target tissues,
including the retinal pigment epithelium and placenta (D’Ambro-
sio et al., 2011). As the archetypal lipocalin (Newcomer and Ong,
2000), RBP folds as a b-barrel with a central hydrophobic ligand636 Cell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc.cavity (Figures 2D and S3) (Cowan et al.,
1990; Zanotti et al., 1993). Bothmutations
substitute threonine for alanine, in codons
73 and 75 of b strand C (Figure 2C), corre-
sponding to residues 55 and 57 in the
mature polypeptide. These alanines face
the ligandpocket (Figure 2D), contact car-
bons C4 and C3 of the retinol b-ionone
ring, respectively (Cowan et al., 1990),
and are completely conserved among
vertebrates (Figure 2E).
Two previously reported RBP4 muta-
tions, p.I59N and p.G93D, were associ-ated with recessive night blindness in compound heterozygous
sisters (Biesalski et al., 1999). They correspond to I41N
and G75D in b strands B and D of the mature protein, after
signal peptide cleavage. These residues also interact with
side groups of the b-ionone ring, and biochemical data sug-
gest G75D and I41N proteins bind retinol poorly (Folli et al.,
2005). Molecular modeling shows that A55T and A57T
proteins can accommodate retinol, under increased strain
due to steric, hydrophilic, and H-bonding effects of the
threonine side chain (Figure S3). To understand the allelic
heterogeneity and pathogenic basis of MAC disease, we sys-
tematically compared properties of wild-type (WT) and mutant
RBPs.
A55T and A57T Proteins Are Stably Secreted
RBP is constitutively expressed by hepatocytes, retained in
the ER and secreted into the bloodstream as holo RBP (Muto
et al., 1972; Soprano and Blaner, 1994), stabilized by three disul-
fide bonds (Selvaraj et al., 2008). We first evaluated how
missense mutations affect RBP synthesis and secretion in trans-
fected HeLa cells (Melhus et al., 1992) by western analysis, using
an N-terminal hemagglutinin (HA) tag (Figure 3A). The size (21 kil-
odalton [kDa]) and abundance of A55T and A57T proteins in 48 hr
conditioned media (CM) were indistinguishable from WT (Fig-
ure 3B). In contrast, G75D and I41N proteins migrated as
42 kDa dimers, or larger multimers (I41N), linked by intermolec-
ular disulfide bonds (Figures 3B and S4). We confirmed this
result using glutaraldehyde cross-linked CM, and compared
intracellular RBP levels using WTKDEL as an ER retention control
(Figure 3C). Intracellular G75D and, to a greater extent, I41N
were elevated, suggesting a partial secretion defect, with no
evidence of ER stress (Figure S4B). We conclude that A55T
and A57T are secreted as stable 21 kDa monomers, whereas
G75D and I41N misfold in the ER, aggregate, and exhibit
increased cellular retention.
A55T and A57T Complex Normally with Transthyretin
Under normal conditions, holo RBP and transthyretin (TTR), a
60 kDa homotetramer (Heller and Horwitz, 1974), are cosecreted
in a 1-to-1 molar ratio as a 76 kDa complex (Kanai et al., 1968).
The large size of this complex prevents renal filtration, allowing
RBP to remain in circulation (Soprano andBlaner, 1994; vanBen-
nekum et al., 2001). In coimmunoprecipitation experiments (Fig-
ures 3D and 3E), human TTR interacted strongly with WT, A55T,
and A57T proteins, but poorly with G75D or I41N. Similar results
were obtained for bovine TTR, present in the media supplement.
To quantitatively assess the RBP-TTR interaction, we performed
reciprocal surface plasmon resonance (SPR) assayswith purified
TTR and recombinant RBPHA or his-RBP (Figure 3F). WT holo
RBP bound TTR with 2- to 3-fold greater affinity than apo RBP,
giving mean steady state Kd values of 0.9 and 2.2 mM respec-
tively, similar to previous reports (Folli et al., 2010; Malpeli et al.,
1996). The affinity of A55T and A57T mutant RBPs was similar
or slightly lower thanWT in buffered saline (HBS). However, inclu-
sion of nonionic surfactant (0.005%Tween) significantly reduced
holo A55T affinity for TTR, presumably by removing retinol (p <
0.001, unpaired t test, and df = 10, see below).
The in vitro behavior of G75D and I41N proteins is consistent
with the absence of immunodetectable serum RBP in p.G93D/
p.I59N compound heterozygotes and reduction of RBP in the
p.I59N/+ parent, in the setting of normal TTR levels (Biesalski
et al., 1999). Conversely, RBP and TTR levels in p.A75T/+ (Family
1, VI-2, VI-3, and VI-7) and p.A73T/+ (Family 3, II-2) carriers were
within normal range (Table S3).
WT and A57T Proteins Coexist in p.A75T/+ Carrier
Plasma
To assess the ratio of allotypes in vivo, total RBP was purified
from obligate carrier VI-2 plasma (Figure S5), digested with
trypsin, and analyzed by mass spectrometry (Figure 4). The pre-
dicted WT and A57T peptides encompassing amino acid 57
differ by 30 Dalton. Consequently, we identified MALDI-TOF
peaks in the 3,100 to 3,220 mass-to-charge ratio (m/z) range
corresponding to WT and A57T tryptic peptides, with a 2-to-1 in-
tensity ratio (Figure 4C). These were verified by tandem mass
spectrometry (MS2) analysis (data not shown) and parallel MS
of RBPHA controls. Since the peptides ionize with equal effi-ciency (Figure 4D), we conclude that A57T constitutes one-third
of circulating RBP in p.A75T/+ heterozygotes.
Because both allotypes were present in carrier plasma,
genomic imprinting is unlikely to explain the skewed transmis-
sion of the MAC disease (Figure S1B). This conclusion is
supported by RT-PCR analysis of F1 mice, which showed com-
parable levels of allelic Rbp4mRNA transcripts in adult and fetal
tissues (Figure S4C).
In principle, the unequal ratio of allotypes could be explained
by a difference in renal filtration. Under normal circumstances,
RBP dissociates from TTR when retinol is delivered to tissues
(Malpeli et al., 1996). Most of the resulting apo RBP is filtered
and metabolized by the kidney, but trace amounts are detected
in urine, at 1%of serum levels (Raila et al., 2005) and are assumed
to represent the RBP content of the glomerular ultrafiltrate pro-
portionally. To test this hypothesis, we evaluated RBP allotypes
in p.A75T/+ carrier urine by MS, but found no evidence for
increased urinary elimination of A57T relative to WT (Figure S6).
A55T and A57T Proteins Bind Vitamin A Poorly
We tested retinol-binding properties of mutant RBPs using two
assays, double radioisotope labeling and fluorescence enhance-
ment. HeLa cells expressingWT or mutant RBPHA were exposed
to 35S-met/cys and 3H-retinol, and the 3H/35S ratio was deter-
mined for RBPHA immunopurified from CM (Figures 5A and
5B). We observed a dramatic reduction in retinol binding, as pre-
dicted by molecular modeling (Figure S3E). A55T bound negli-
gible 3H-retinol, whereas A57T bound 16% of WT levels. G75D
and I41N mutants also bound very little vitamin A, as expected
given their misfolded structures. RBP activity is evidently more
sensitive to a threonine substitution at position 55 than 57,
consistent with X-ray data placing retinol closer to Ala55 (3.6A˚)
than Ala57 (4A˚) (Cowan et al., 1990).
Retinol fluorescence intensity increases 15-fold when it oc-
cupies the RBP ligand pocket (Cogan et al., 1976). Accordingly,
we added 1 to 5,000 nanomolar (nM) retinol to apo RBPHA,
purified under native conditions, and measured fluorescence
(excitation [ex] 330 nanometer [nm] and emission [em] 460 nm)
in PBS (Figure 5C, filled symbols). Surprisingly, A55T and A57T
both bound retinol well in this assay, with affinities similar to
WT (Kd 80 nM). These results are consistent with SPR analysis
of holo and apo forms interacting with TTR in HBS (Figure 3F),
but differ sharply from the radioisotope data showing the mu-
tants bind little or no vitamin A (Figure 5B).
WTholoRBP is relatively resistant to temperature,pHextremes,
and nonpolar solvents (Cogan et al., 1976; Raz et al., 1970), but
sensitive to low ionic strength (Peterson,1971).Ourdisparatefind-
ingsmay be reconciled if A55T and A57T substitutions destabilize
RBP contacts with retinol, particularly under adverse environ-
mental conditions, increasing the probability that ligand is
released to the solvent. Whereas the initial fluorescence assay
was performed in PBS (Figure 5C, closed symbols), our 3H-retinol
binding assay involved sequential washes in PBS containing 1%
Triton X-100 and 0.5% deoxycholate (Figure 5A). We therefore
systematically tested retinol binding in nonpolar and amphipathic
environments (Figure 5D), including a dispersion of phosphatidyl-
choline (PC) vesicles (Figure 5C, open symbols), to more closely
approach in vivo conditions. Within the ER, bloodstream, andCell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc. 637
Figure 3. A55T and A57T Proteins Are Secreted as Stable RBP Monomers and Interact with TTR
(A) Test of RBPHA synthesis, secretion, and integrity.
(B) HA western analysis of CM, electrophoresed under native or denaturing conditions, before or after crosslinking.
(C) Western blot of cell lysates, with a-tubulin loading control.
(D) RBP-TTR binding assay in tissue culture. Brown circles, TTR homotetramers and blue bars, RBP monomers.
(E) Western blot of HA immunoprecipitates probed in sequence with TTR and HA antibodies.
(F) SPR analysis of RBP-TTR binding in vitro. (Top) Sensorgrams show a TTR concentration series interacting with apo his-RBPs on a biotin capture chip. (Middle)
Steady state isotherms for apo and holo RBPHA binding to TTR. (Bottom) Histogram of Kd values. Error bars give the SEM for nonlinear regression. See also
Figure S4.
638 Cell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc.
Figure 4. MS of RBP Proteotypes in
p.A75T/+ Carrier Plasma
(A) Tryptic peptides encompassing residue 57.
Modified peptides (asterisks) arise from alkylation
of methionine 53 (A).
(B) MALDI-TOF spectrum of RBP from control
human plasma, indicating the critical m/z region
(red box). The y axis (ions detected) reflects rela-
tive intensity.
(C) Expanded view of control (top) and carrier
(bottom) spectra from 3,100 to 3,250 m/z. Single-
ionization peaks corresponding to WT (red lines)
and A57T (green lines) proteins are marked.
(D) MALDI-TOF spectra for recombinant RBPHA.
The invariant 3,223.3 m/z peak (human keratin,
a common contaminant) serves as an internal
standard. See also Figures S5 and S6.tissue interstitial space,RBP iscontinuouslyexposed tophospho-
lipid membranes and lipoprotein particles (van Meer et al., 2008).
Indeed, retinol-binding activity of the mutant proteins was hyper-
sensitive to ethanol, detergents, and phospholipid vesicles,
following an A55T > A57T > WT allelic series. Almost no retinol
was bound by A55T in 0.1% PC (Kd > 30 mM).
Our in vitro data predict that RBP4 heterozygotes may have
reduced circulating retinol. Indeed, three p.A75T/+ obligate car-
riers had fasting serum vitamin A levels below the lower normal
limit (Table S3), ranging from 50%–60% of the reference mean,
and plasma retinol fluorescence was reduced (Figure S5B).
Increased Binding of A55T and A57T Proteins to the
STRA6 Receptor
STRA6, or stimulated by RA 6 (Bouillet et al., 1997), is the trans-
membrane receptor for RBP that mediates cellular uptake ofCell 161, 634–6vitamin A (Kawaguchi et al., 2007). At
target tissues, holo RBP binds STRA6
extracellular loop 6 with high affinity (Ka-
waguchi et al., 2008). Following transfer
of vitamin A into cells, apo RBP dissoci-
ates from the receptor, allowing a new
holo RBP molecule to dock (Kawaguchi
et al., 2007).
To examine binding of A55T and A57T
proteins to STRA6, we performed two
sets of experiments. We first applied
35S-labeled apo WT, holo WT, A55T, or
A57T RBP in parallel to human embryonic
kidney (HEK) 293T cells transfected with
STRA6myc or control expression vectors
and measured 35S-RBP bound after one
hr (Figures 6A–6C). In this assay, apo
RBP had 3-fold lower steady state bind-
ing than holo RBP. More dramatically,
STRA6+ cells bound 4 to 7 times more
mutant apo RBP than WT holo RBP (p <
0.002, unpaired t tests, and df = 4). These
findings, and the mass spectroscopy
data (Figure 4), suggest that competitionmay occur betweenmutant andWTRBPmolecules at STRA6 re-
ceptors in vivo. To explore this possibility, we mixed 8–250-fold
excess unlabeled holoWTwith 35S-labeled RBPHA in parallel as-
says. In each case, the unlabeled WT competitor displaced
much less mutant 35S-RBP than expected if the binding affinities
were equivalent.
To characterize the STRA6-RBP interaction more precisely,
we determined the binding affinity (Kd) and rate constant for
the approach to equilibrium of mutant and WT RBPs, using a
sensitive ELISA method (Figure S7) to measure RBPHA bound
to cells and released into the media. These assays show that
the mutant proteins have a 30–40-fold greater affinity for
STRA6 than WT (Figure 6D), with Kd values of 1.9 nM (A55T)
and 1.5 nM (A57T) compared to 59 nM (WT, p < 0.001, unpaired
t tests, and df = 6). In principle, two kinetic mechanisms
can explain this striking result, which is central to disease46, April 23, 2015 ª2015 Elsevier Inc. 639
Figure 5. A55T and A57T Proteins Bind Retinol Poorly in a Mixed Aqueous-Lipid Environment
(A) 3H-retinol binding assay.
(B) (Left) 3H-retinol binding data normalized to WT. (Right) Autoradiogram showing secreted 35S-RBPHA in CM.
(C) (Left) In vitro retinol binding profiles for WT and mutant RBPHA, measured by fluorescence in PBS ±0.1% a-L-PC, with 380 nM protein. (Right) Histogram
showing similar Kd values in PBS.
(D) (Left) Normalized retinol binding curves in PBS with 0 to 50% ethanol. (Right) Increased sensitivity of mutant RBPs in an amphipathic environment, measured
by loss of retinol fluorescence after exposure to detergent micelles (1% Tx-100, 0.5% DOC) in PBS. Error bars show the SD (fluorescence plots) or SEM
(histograms) for three parallel assays.pathogenesis—either the mutant RBP-STRA6 complex dissoci-
ates more slowly or the mutant RBPs bind the receptor more
rapidly. To distinguish these possibilities, we measured the
release of RBP from STRA6+ and control cells at 25C and
37C (Figure 6E) and calculated forward (kon) and reverse (koff)
rate constants. As these data show, the major consequence of
the mutations is to increase kon by 25–50 fold (p < 0.001, un-
paired t tests, df = 42), with no significant change in koff (Fig-
ure 6F; Table S4). The pathogenic RBPs thus bind STRA6 with
much higher affinity than WT, yet carry little or no vitamin A.
DISCUSSION
Here, we identify RBP4 mutations as the cause for autosomal
dominant MAC with incomplete penetrance and skewed
maternal transmission. These findings demonstrate a new
mode of inheritance in mammals, whereby phenotypic expres-
sion is governed by maternal genotype. Our conclusions are
supported by linkage analysis, the discovery of independent
alleles, evolutionary conservation, the established role of vitamin
A in eye morphogenesis, and convergent biochemical, func-
tional, modeling and clinical data which prove A55T and A57T
proteins have impaired retinol binding, but resist renal filtration
and interact strongly with STRA6. Together, these data provide
a simple, but elegant mechanism for disease pathogenesis.
A Unified Disease Model
A55T and A57T RBPs act as dominant-negative proteins, most
likely by blocking vitamin A delivery at the STRA6 receptor (Fig-640 Cell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc.ure 7A). Mutant and WT proteins coexist in plasma (Figure 4)
and are therefore both secreted. Following translation, A55T
and A57T proteins may transiently bind vitamin A in the hepato-
cyte ER, but if so, are likely to lose a significant fraction of their
retinol content in the amphipathic environments of the ER-Golgi
compartment and bloodstream (Figure 5). They are otherwise
stable and partner with TTR (Figure 3). At the target cell, mutant
RBPs bind STRA6 receptors more avidly than WT (Figure 6),
with faster association kinetics, increased affinity, and thus
longer net occupancy, creating a molecular restriction point.
Consequently, delivery of vitamin A from holo RBP should be
disrupted.
When the RBP4 mutation is transmitted by the mother, this
bottleneck effect is iterated twice, first, at the placenta, involving
maternal-derived RBP, and later at the developing eye
primordia, involving fetal-derived RBP (Figure 7B). In this setting,
retinol delivery to fetal tissues may be dramatically reduced—
and penetrance of eye phenotypes increased—compared to
paternal transmission of the same mutation, creating a maternal
inheritance pattern that resembles genomic imprinting, but does
not involve chromatin or DNA modification. This model is sup-
ported by data showing that STRA6 is localized in the placenta
and fetal eye (Bouillet et al., 1997; Kawaguchi et al., 2007) and
that maternal RBP does not cross the placental barrier in mice
(Quadro et al., 2004). Furthermore, RBP is expressed in extraem-
bryonic tissues that directly participate in retinol transfer across
the maternal-fetal interface, including the visceral yolk sac (Jo-
hansson et al., 1997; Sapin et al., 1997; Soprano et al., 1986;
Ward et al., 1997). Recently, STRA6 has been shown to mediate
Figure 6. A55T and A57T Proteins Bind the STRA6 Membrane Receptor with Greater Affinity Than WT
(A) STRA6 radioligand binding assay.
(B) STRA6myc expression in HEK293T cultures. (Left) Fluorescence micrographs of transfected cells immunostained for myc (green) with nuclear counterstain
(blue). Scale bars, 40 mm. (Right) Western blot simultaneously probed with antibodies to human STRA6 (72 kDa) and a-tubulin (50 kDa).
(C) Histogram showing binding of 5 pM 35S-labeled WT, A55T, or A57T RBPHA proteins in the absence (black) or presence (gray) of 8- or 250-fold excess un-
labeled (cold) holo WT competitor.
(D) Quantitative equilibrium analysis of RBP-STRA6 interaction by immunoassay. (Left) Binding isotherms and reciprocal plots of apoRBPHA ELISA data. Relative
RBP levels are given in counts per second (cps) emitted light, after subtracting nonspecific binding to control cells. (Right) Histogram of Kd values. The mutant
RBPs bind to the receptor with 30–40 fold greater affinity than WT.
(E) Kinetic analysis of the RBP-STRA6 interaction. Release of bound apo RBPHA to the media over time, from saturated STRA6+ cells at 25C.
(F) Histogram comparing STRA6 association (kon) and dissociation (koff) rate constants calculated from binding data. The A55T and A57T mutations greatly
increase the on rate for RBP binding to STRA6. See also Figure S7; Table S4. Error bars show the SEM for three parallel assays or nonlinear regression of triplicate
measurements.retinol efflux from cells as well as influx, loading extracellular apo
RBP with cytoplasmic vitamin A (Kawaguchi et al., 2012). This
bidirectional mode may be critical during early development,
as fetal RBP originating from the visceral yolk sac or liver can,
in principle, ferry retinol stepwise between different STRA6+
cells. Because the mutant RBPs are predicted to disrupt
STRA6 docking on both sides, this relay mechanism may be
highly sensitive to dominant-negative effects. The labyrinthine
zone of the murine chorioallantoic placenta, for example, is a
major site of maternal-fetal exchange that strongly expresses
STRA6, but not RBP (Bouillet et al., 1997; Johansson et al.,
1997). Likewise in humans, RBP is expressed by the maternal
decidua, but not by villous trophoblasts (Johansson et al., 1999).
When transmitted by the father, the RBP4 mutation can only
disrupt vitamin A transfer beyond the placenta. Consequently,
the severity of fetal VAD, and the genetic penetrance frommales,
should be comparatively low. Clinical phenotypes may only be
expressed when vitamin A supplied to the placenta is dimin-
ished, notably in twin gestation (individual VI-2), where retinol
input is divided between two embryos.Structural Basis for Enhanced STRA6 Binding
RBP is the archetypal lipocalin, an ancient protein family repre-
sented in nearly all life forms, including mammals, invertebrates,
fungi, and eubacteriae (Flower, 1996; Newcomer and Ong,
2000). Its ligand pocket is formed by eight anti-parallel beta
strands (A–H) with alternating hydrophilic and hydrophobic
amino acids, the latter stabilizing retinol. The orientation of the
A-B loop, specifically G34-L35-F36-L37, is the only major struc-
tural difference between apo and holoRBP crystals at neutral pH
(Zanotti et al., 1993). Threonine substitutions at Ala55 or Ala57,
conserved sites deep within the pocket, impair retinol binding
and, paradoxically, enhance STRA6 binding. Because these
sites are located in the interior of the protein and thus unlikely
to contact STRA6, the mutations must increase receptor binding
indirectly, by altering RBP conformation. The striking decrease in
Kd is driven by a large increase in the association rate constant
(kon) with no apparent change in dissociation kinetics (koff). While
relatively unusual (Anderson et al., 1998), a small number of pro-
tein-receptor affinity mutations are known to specifically affect
kon (Lahti et al., 2011; Lengyel et al., 2007). Our findings stronglyCell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc. 641
Figure 7. Model for Disease Pathogenesis,
Dominant Inheritance, and Maternal Effect
on Penetrance
(A) RBP life cycle in WT (top) and heterozygous
(bottom) individuals. In mutation carriers, A55T or
A57T are cosecreted with WT proteins from the
liver and/or extraembryonic tissues (yolk sac).
Each RBP circulates in the maternal or fetal
bloodstream in a stable complex bound to TTR,
but most of the mutant proteins lack retinol. Upon
reaching target tissues, the mutant RBPs bind
STRA6 receptors with much higher affinity than
WT, acting as dominant-negative particles that
block vitamin A delivery.
(B) Basis for maternal inheritance. Skewed pene-
trance arises from functional ‘‘bottlenecks’’ that
occur at sequential RBP-STRA6 interaction sites
in the placenta and fetal eye. Disruption of vitamin
A transfer at both levels, coupledwith lowmaternal
dietary retinoids (orange and red lines), predispose
the fetus to MAC disease when the trait is mater-
nally transmitted. Vitamin A deficiency, VAD.suggest that RBP-STRA6 docking involves a conformational
adaptation of RBP and that this initial step, rather than diffusion,
limits the binding reaction, consistent with a selected-fit model
(Weikl and von Deuster, 2009). Complementary changes in
STRA6 foldingmay further stabilize the ligand-receptor complex.
The RBP lipocalin undergoes reversible transformation to a
molten globule state as pH or solvent polarity is reduced (Calder-
one et al., 2003; Greene et al., 2006). This cooperative unfolding
has been proposed to occur naturally in the local acidic environ-642 Cell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc.ment at the cell surface, favoring retinol
release (Bychkova et al., 1998), and
may be potentiated by interaction with
STRA6. We propose that the A55T and
A57T mutations, by altering the shape,
polarity, and hydrophilicity of the retinol
pocket, lower the activation energy for
this transition. Consequently, a significant
fraction of the mutant RBP population
may exist in a partially melted state under
normal physiological conditions. These
molecules, which may resemble WT in-
termediates in the RBP-STRA6 binding
reaction, presumably account for the
enhanced retinol release observed in the
presence of organic solvents, surfac-
tants, or phospholipid vesicles. Indeed,
retinol dissociates from the mutant
RBPs with biphasic kinetics, in PBS
following addition of Tx-100 and deoxy-
cholate (DOC), consistent with the exis-
tence ofR2 discrete holo conformations
(Figure 5D).
Despite their increased forward reac-
tion rates, the mutant apo RBPs appear
to undock normally from STRA6 (Fig-
ure 6E). Likewise, mutant apo and holoRBPs bind TTR with an intrinsic affinity similar to WT (Figure 3)
and are thus retained in carrier plasma (Figure 4). Indeed, the
enhanced binding of mutant RBP to STRA6+ cell surfaces may
in part explain the 1:2 ratio of mutant-to-WT protein in carrier
plasma, which cannot be accounted for by unequal urinary
loss (Figure S6). RBP normally contacts TTR via three external
loops (Figure 2D), which form the opening to the retinol pocket,
and the C terminus (Newcomer and Ong, 2000). Although the
structural details are not known, these same features are likely
to mediate the interaction between RBP and STRA6, allowing
retinol to exit (Kawaguchi et al., 2008). For steric reasons, the
RBP-TTR complex must dissociate before receptor binding
can occur. This step is driven by a 20-fold difference in the
steady state affinity of RBP for STRA6 versus TTR. The alanine
substitutions affect RBP binding to former, but not the latter.
Structural studies of the mutant proteins may shed light on the
conformational steps necessary for STRA6 docking and dissoci-
ation and vitamin A release.
RBP4Mutations, Diet, and Vitamin A Physiology
Among organs, the eye is most frequently affected in animal
models of vitamin A deficiency (Hale, 1933; See and Clagett-
Dame, 2009; Warkany and Schraffenberger, 1946; Wilson
et al., 1953). Our findings are consistent with this pattern. Despite
a global reduction in vitamin A available to the embryo, pheno-
types in Family 1 are limited to the eye. Given the central role
of retinoids in light perception, this unique sensitivity is striking
andmay reflect an evolutionary origin of RA signaling in the visual
system (Campo-Paysaa et al., 2008; Drager et al., 2000). Like-
wise, in humans, total loss of RBP4 is only associated with night
blindness, retinal dystrophy, and chorioretinal coloboma (Biesal-
ski et al., 1999; Cukras et al., 2012).
In addition to retinol, other forms of vitamin A (principally retinyl
esters) are delivered to the placenta via chylomicron lipoprotein
particles (D’Ambrosio et al., 2011; Wassef and Quadro, 2011).
Indeed, 25% of postprandial retinoids, including retinyl esters
(RE) and a/b-carotenoids, travel directly to extrahepatic tissues
from intestinal enterocytes via this parallel system, with no
involvement of RBP (Goodman et al., 1965). However, because
chylomicron RE are rapidly cleared (Berr, 1992), RBP accounts
for 95%–99% of circulating retinoids in the fasting state (So-
prano and Blaner, 1994). Accordingly, the extent and timing of
maternal RE consumption during pregnancy, along with other
genetic and/or environmental modifiers, may account for the
variable penetrance. For women carrying an RBP4 mutation,
careful dietary supplementation with extra vitamin A (RE) in
divided doses may be indicated to minimize risk of congenital
eye malformations in offspring.
Recent nutritional studies showed thatRbp4/mouse pups
born from Rbp4 / dams are normal when mothers were fed
diets replete with RE (Quadro et al., 2005). However, these
pups developedmicrophthalmia or anophthalmia in the absence
of dietary retinoids and the severity was determined by maternal
vitamin A status. In our study, clinical phenotypes were roughly
correlated with the magnitude of biochemical effects (Figure 5).
Thus, both affected males in Family 2 (A55T) had neurodevelop-
mental delay in addition to anophthalmia. The discovery of genes
that modify plasma retinoid levels, apart from RBP4 and TTR
(Mondul et al., 2011), may shed more light on this disease.
Nutritional Mechanism for Maternal Inheritance of
Human Genetic Disease
Maternally skewed inheritance has been reported for other birth
defects, including congenital heart disease (Burn et al., 1998;
Nora and Nora, 1987), but the molecular basis is unknown. A
study of scoliosis identified gestational hypoxia as an environ-
mental factor that disrupts fibroblast growth factor signalingand somitogenesis, increasing penetrance of Notch pathway de-
fects (Sparrow et al., 2012). Genetic vitamin A deficiency has
been previously suggested as a potential factor for eye malfor-
mations (Hornby et al., 2003). Dominant-negative RBP4 alleles
provide a further example of gene x environment effects. Unlike
other modes of maternal inheritance, e.g., transmission of
ooplasmic mRNA, mitochondrial DNA mutations, or genomic
imprinting, these alleles affect fetal and maternal metabolism at
a functional level. The sex-specific penetrance has a physiolog-
ical basis. Our findings highlight the importance of maternal-fetal
nutrition and may apply broadly to congenital disease.
EXPERIMENTAL PROCEDURES
Clinical Data
Human studies were approved by the University of Michigan (UM); University
of California, Davis; and Einstein Medical Center Institutional Review Boards,
and informed consent was obtained from all subjects. Eye exams, fundus
photography, and magnetic resonance imaging (MRI) were performed at UM
(Table S1). Blood tests for retinol, RBP, and TTR (prealbumin) were performed
on carrier samples collected after a 12 hr fast (Table S3). MS of plasma and
urine samples and other clinical studies are detailed in the Extended Experi-
mental Procedures.
Genetic Analysis
Family 1 genotypes were determined at 51 simple sequence length polymor-
phism (SSLP) and 6,070 SNP loci using blood, saliva, or buccal DNA. SNPs
were assessed using the HL12 BeadChip platform and BeadStudio software
(Illumina). Genetic mapping was performed in three steps. Exclusion tests
were performed by comparing probands using SSLP markers flanking 23
candidate loci (Table S2). Multipoint linkage analysis was then performed on
a core pedigree consisting of all living affected individuals, obligate carriers,
and spouses (n = 20) usingMerlin v1.1.2 (Abecasis et al., 2002). Finally, linkage
analysis was extended to include all collected (n = 33; Figures S1C and S1D)
and nodal family members. LOD scores from two subpedigrees (Figure S1D)
were summed, discarding duplicate phenotypic information (Bellenguez
et al., 2009) and applying an AD inheritancemodel with uniform or sex-specific
penetrance, estimated from the pedigree.
To identify RBP4 coding variants, we screened 75 unrelated MAC probands
and 307 controls (National Institute of Neurological Disorders and Stroke
panel) by PCR Sanger sequencing (Table S5) and queried the EVS Exome
Variant database. Chromosome 10q haplotypes of Families 2 and 3 were
compared using the Omni1-Quad SNP platform (Illumina).
RBP Secretion and TTR Interaction Assays
Parallel HeLa cultures were transfected with pUS2-RBPHA vectors expressing
WT,mutant (A55T, A57T, G73D, or I41N), or ER retention (WTKDEL) human RBP
proteins with an N-terminal HA epitope, or control plasmid (Table S6). After
48 hr, CM and cell lysates were electrophoresed through native or denaturing
polyacrylamide gels and compared by HA western analysis. To evaluate RBP
multimerization, CM was crosslinked in 0.5% volume per volume (v/v) glutar-
aldehyde for 30 min, boiled with or without 2 mM 2-mercaptoethanol (bME),
and electrophoresed. To assess RBP-TTR binding in culture, HeLa cells
were cotransfected with pUS2-TTRmyc and WT or mutant pUS2-RBPHA plas-
mids. Secreted RBPHA complexes were immunopurified from CMwith anti-HA
agarose beads (Sigma), washed in PBS, and tested for TTR by western anal-
ysis. To fully assess RBP-TTR binding in vitro, reciprocal SPR assayswere per-
formed using a Biacore T100 system (GE Healthcare) and biotin capture chip
with human plasma TTR (Sigma) and HA- or polyhistidine-tagged RBP purified
from HeLa CM.Molecular cloning, cell culture, protein biochemistry, SPR, and
data analysis are detailed in the Extended Experimental Procedures.
Retinol Binding Assays
To assess retinol binding to RBP in culture, HeLa cells were transfected with
WT or mutant pUS2-RBPHA plasmids in Dulbecco’s Modified Eagle mediaCell 161, 634–646, April 23, 2015 ª2015 Elsevier Inc. 643
(DMEM) containing 10% delipidated fetal bovine serum (FBS), metabolically
labeled with 6 microcuries per milliliter (mCi/ml) 35S-methionine and -cysteine
in serum-free DMEM for 1 hr, and exposed to 8.25 mCi/ml 3H-retinol (NEN Per-
kin-Elmer) for an additional 3 hr. Secretion of 35S-labeled RBP in the CM was
assessed by gel electrophoresis and autoradiography. Radiolabeled RBPHA
was immunopurified from CM using anti-HA agarose beads, washed three
times in PBS containing 1% Triton X-100, 0.5% sodium DOC, and eluted in
2% sodium dodecyl sulfate (SDS). The 3H/35S isotope ratio was measured
by liquid scintillation counting (LSC) and normalized to WT.
For in vitro titration assays, recombinant apo RBPHA was immunopurified
from serum-free HeLa CM, eluted with HA peptide (Anaspec), and dialyzed
into PBS. Homogeneity was verified by gel electrophoresis. Equal amounts
ofWT, A55T, or A57T RBPHA proteins were loaded with 0 to 5 mM fresh all-trans
retinol for 1 hr in PBS. Binding was quantified by retinol fluorescence (ex
330 nm and em 460 nm) enhancement (Cogan et al., 1976) using a microplate
reader. To assess binding in nonpolar or amphipathic conditions, parallel as-
says were performed in PBS with 0 to 50% ethanol; 1% Triton X-100, 0.5%
DOC for 0 to 90 min; or 0.1% a-L-PC vesicles dispersed in 5% n-butanol.
STRA6-RBP Binding
Radioligand Assay
Immunopurified 35S-labeled apoWT, holoWT, A55T, or A57T RBPHA (5 pico-
molar [pM] at 1.2 3 107 counts per minute/picomole specific activity) was
added, with or without an 8- or 250-fold excess unlabeled holoWT competitor,
to paired HEK293T cultures, transfected with pUS2-STRA6myc or pUS2 vector
plasmid DNA. After 1 hr at 37C, the cells were gently washed with prewarmed
PBS (Kawaguchi et al., 2007) and the amount of bound 35S was determined by
LSC. Receptor-specific binding was calculated by subtracting the vector con-
trol. STRA6myc expression was verified by myc immunofluorescence and
STRA6 western analysis.
Equilibrium and Kinetic Analysis
STRA6+ or control HEK293T cells were plated on poly-D-lysine (PDL) coated
dishes and incubated with CM containing 0–80 mg/ml A55T, A57T, or WT apo
RBPHA and 0.5% BSA for 90 min at 37C. For Kd analysis, monolayers were
washed with ice-cold Hanks balanced salt solution (HBSS) and bound RBP
was eluted with 25 mM glycine HBSS pH 3. For kinetic analysis, monolayers
were washed with DMEM 0.5% BSA and dissociation was followed at 25C
or 37C by sampling the media at time points from 0 to 90 min. The concentra-
tion of RBPHA was determined by an ELISA (Figure S7). The immunoassay,
saturation binding and kinetic methods, and quantitative analysis are detailed
in the Extended Experimental Procedures.
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